DDR1 and neoplasm: In recent years, PDX and organoid models, both of which directly originate from human tumor specimens, have emerged as promising approaches for translational research in cancer treatment.[37] To investigate the therapeutic potential of DDR1 as a treatment target for GC, a highly selective inhibitor of DDR1, 7rh benzamide, was used to block DDR1 signaling in PDX and organoid models.